Modality
Small Molecule
MOA
PI3Ki
Target
WEE1
Pathway
Neuroinflam
PBCWM
Development Pipeline
Preclinical
May 2020
→ Oct 2030
PreclinicalCurrent
NCT03701127
2,305 pts·WM
2022-10→2030-10·Terminated
NCT03481824
1,186 pts·WM
2020-05→2028-10·Not yet recruiting
3,491 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-10-172.5y awayInterim· WM
2030-10-224.6y awayInterim· WM
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Not yet…
Preclinical
Termina…
Catalysts
Interim
2028-10-17 · 2.5y away
WM
Interim
2030-10-22 · 4.6y away
WM
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03701127 | Preclinical | WM | Terminated | 2305 | FEV1 |
| NCT03481824 | Preclinical | WM | Not yet recr... | 1186 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |